Key Highlights

  • Third-quarter 2026 Revenue came to USD 618.9 million on November 3, 2026, a decline of 11.6% from USD 699.9 million, while Point of Care sales slid 27.3% to USD 119.6 million.
  • The GAAP net loss totaled USD 53.8 million, or USD 0.78 a share, compared with a USD 733.0 million loss, or USD 10.78 a share, one year earlier, and adjusted diluted EPS dropped to USD 0.31 from USD 0.80.
  • Full-year adjusted EPS guidance tightened to USD 0.65 to USD 0.70 from USD 0.65 to USD 0.90, and revenue expectations were trimmed to USD 2.52 billion to USD 2.54 billion.
  • Borrowings of about USD 2.94 billion compared with cash of USD 166.4 million at September 27, 2026, and free Cash Flow for the quarter was only USD 0.3 million.

Point of Care Slump Drives the Revenue Decline

QuidelOrtho (NASDAQ:QDEL) published results for the quarter ended September 27, 2026 on November 3, 2026. Labs revenue dropped 5.5% to USD 353.2 million and immunohematology held flat at USD 142.0 million, while Point of Care fell 27.3% amid a weaker respiratory season. The diagnostics maker generated adjusted EBITDA of USD 148.0 million, a 23.9% Margin versus 25.3% previously, and posted a GAAP operating loss of USD 7.5 million. Management described Labs and Immunohematology as solid, placing the weakness in respiratory testing, which can swing with the severity of flu and COVID seasons. Nine-month revenue totaled USD 1,869.6 million against USD 2,006.6 million a year earlier.

A Large Prior-Year Loss Distorts the EPS Comparison

A published market data screen lists a 1 year EPS change of 122.63% and a price of about USD 14.14, up 0.36%, but the undated screen could not be matched to the filing. GAAP loss per share narrowed from USD 10.78 to USD 0.78 largely because the year-earlier loss of USD 733.0 million was far larger, and the release extract did not state that loss's cause, so none is assumed. On the adjusted basis, EPS fell about 61%, from USD 0.80 to USD 0.31, simple arithmetic. Dividing the prior-year loss by its per-share figure implies about 68 million shares, which puts Market Value near USD 1 billion, a rough estimate and not a verified market capitalization. The share count and price were not matched to a filing.

Guidance Trim, Restructuring and a Heavy Debt Load

The company shaved the top of its 2026 ranges, with adjusted EBITDA now USD 540 million to USD 545 million against USD 540 million to USD 560 million previously, and adjusted EPS of USD 0.65 to USD 0.70. It expects more than USD 80 million of annual savings in 2027, plus one-time restructuring charges of about USD 30 million to USD 35 million in the fourth quarter as it reorganizes around Core Diagnostics and Point of Care Diagnostics. Borrowings of about USD 2.94 billion dwarf USD 166.4 million of cash, and nine-month free cash flow was negative USD 202.8 million, a central risk for QuidelOrtho (NASDAQ:QDEL).

Where Things Stand

Mainly weaker respiratory demand, plus the company trimming the top of its earlier range. QuidelOrtho (NASDAQ:QDEL) still reports solid Labs and Immunohematology results, but the 27.3% Point of Care drop, adjusted EPS of USD 0.31 and a leveraged Balance Sheet explain the trim. The USD 80 million 2027 savings target and the fourth-quarter restructuring charges are next to watch, with the coming respiratory season the swing factor. The material reviewed gave no verified date for the next report, and guidance remains an estimate.